Efficacy and safety of HER2-targeted therapies in biliary tract cancer: A systematic review and meta-analysis of early phase clinical trials. 3-year, 4-year and 5-year OS rate of patients who receive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback